256 related articles for article (PubMed ID: 28964116)
21. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
[TBL] [Abstract][Full Text] [Related]
22. Kv1.5 is an important component of repolarizing K+ current in canine atrial myocytes.
Fedida D; Eldstrom J; Hesketh JC; Lamorgese M; Castel L; Steele DF; Van Wagoner DR
Circ Res; 2003 Oct; 93(8):744-51. PubMed ID: 14500335
[TBL] [Abstract][Full Text] [Related]
23. Dynamics and modulation studies of human voltage gated Kv1.5 channel.
Bhuyan R; Seal A
J Biomol Struct Dyn; 2017 Feb; 35(2):380-398. PubMed ID: 26786269
[TBL] [Abstract][Full Text] [Related]
24. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current.
Lagrutta A; Wang J; Fermini B; Salata JJ
J Pharmacol Exp Ther; 2006 Jun; 317(3):1054-63. PubMed ID: 16522807
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
26. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety.
Li D; Sun H; Levesque P
Cardiovasc Hematol Agents Med Chem; 2009 Jan; 7(1):64-75. PubMed ID: 19149545
[TBL] [Abstract][Full Text] [Related]
27. Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.
Wettwer E; Hála O; Christ T; Heubach JF; Dobrev D; Knaut M; Varró A; Ravens U
Circulation; 2004 Oct; 110(16):2299-306. PubMed ID: 15477405
[TBL] [Abstract][Full Text] [Related]
28. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.
Burashnikov A; Barajas-Martinez H; Hu D; Robinson VM; Grunnet M; Antzelevitch C
J Cardiovasc Pharmacol; 2020 Aug; 76(2):164-172. PubMed ID: 32453071
[TBL] [Abstract][Full Text] [Related]
29. Atrial fibrillation: Therapeutic potential of atrial K
Ravens U; Odening KE
Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
[TBL] [Abstract][Full Text] [Related]
30. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation.
Tamargo J; Caballero R; Gómez R; Delpón E
Expert Opin Investig Drugs; 2009 Apr; 18(4):399-416. PubMed ID: 19335273
[TBL] [Abstract][Full Text] [Related]
31. Populations of in silico myocytes and tissues reveal synergy of multiatrial-predominant K
Ni H; Fogli Iseppe A; Giles WR; Narayan SM; Zhang H; Edwards AG; Morotti S; Grandi E
Br J Pharmacol; 2020 Oct; 177(19):4497-4515. PubMed ID: 32667679
[TBL] [Abstract][Full Text] [Related]
32. Novel approaches for pharmacological management of atrial fibrillation.
Ehrlich JR; Nattel S
Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
[TBL] [Abstract][Full Text] [Related]
33. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.
Burashnikov A; Barajas-Martinez H; Hu D; Nof E; Blazek J; Antzelevitch C
J Cardiovasc Pharmacol; 2012 Jun; 59(6):539-46. PubMed ID: 22370957
[TBL] [Abstract][Full Text] [Related]
34. Analysis of electropharmacological effects of AVE0118 on the atria of chronic atrioventricular block dogs: characterization of anti-atrial fibrillatory action by atrial repolarization-delaying agent.
Kambayashi R; Hagiwara-Nagasawa M; Ichikawa T; Goto A; Chiba K; Nunoi Y; Izumi-Nakaseko H; Matsumoto A; Takahara A; Sugiyama A
Heart Vessels; 2020 Sep; 35(9):1316-1322. PubMed ID: 32346771
[TBL] [Abstract][Full Text] [Related]
35. In silico assessment of genetic variation in KCNA5 reveals multiple mechanisms of human atrial arrhythmogenesis.
Colman MA; Ni H; Liang B; Schmitt N; Zhang H
PLoS Comput Biol; 2017 Jun; 13(6):e1005587. PubMed ID: 28622331
[TBL] [Abstract][Full Text] [Related]
36. Vernakalant does not alter early repolarization or contractility in normal and electrically remodelled atria.
van Hunnik A; Nasrallah H; Lau DH; Kuiper M; Verheule S; Schotten U
Europace; 2018 Jan; 20(1):140-148. PubMed ID: 28449044
[TBL] [Abstract][Full Text] [Related]
37. Atrial-Selective Potassium Channel Blockers.
Voigt N; Dobrev D
Card Electrophysiol Clin; 2016 Jun; 8(2):411-21. PubMed ID: 27261831
[TBL] [Abstract][Full Text] [Related]
38. Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
Knobloch K; Brendel J; Rosenstein B; Bleich M; Busch AE; Wirth KJ
Med Sci Monit; 2004 Jul; 10(7):BR221-8. PubMed ID: 15232496
[TBL] [Abstract][Full Text] [Related]
39. Voltage- and time-dependent block by perhexiline of K+ currents in human atrium and in cells expressing a Kv1.5-type cloned channel.
Rampe D; Wang Z; Fermini B; Wible B; Dage RC; Nattel S
J Pharmacol Exp Ther; 1995 Jul; 274(1):444-9. PubMed ID: 7616429
[TBL] [Abstract][Full Text] [Related]
40. Atrial antifibrillatory effects of structurally distinct IKur blockers 3-[(dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in dogs with underlying heart failure.
Regan CP; Kiss L; Stump GL; McIntyre CJ; Beshore DC; Liverton NJ; Dinsmore CJ; Lynch JJ
J Pharmacol Exp Ther; 2008 Jan; 324(1):322-30. PubMed ID: 17967939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
